Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 6/20 | 0.39 |
| ▸ | TYMP | P19971 | 1/20 | 0.37 |
| ▸ | TK2 | O00142 | 8/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2684991 | 0.84 | TYMP (0.38) | TK1TYMPTK2 | |
| SCHEMBL5349908 | 0.84 | TK1 (0.39) | TK1TK2 | |
| SCHEMBL5199538 | 0.79 | SMN1; SMN2 (0.38) | TK1TYMPTK2 | |
| SCHEMBL13417629 | 0.78 | TYMP (0.44) | TK1TYMPTK2 | |
| SCHEMBL2153216 | 0.78 | LMNA (0.44) | TK1TYMPTK2 | |
| SCHEMBL5366400 | 0.77 | KMT2A (0.40) | TK1TYMP | |
| SCHEMBL8150170 | 0.76 | TK1 (0.41) | TK1TK2 | |
| SCHEMBL6924149 | 0.75 | TK1 (0.39) | TK1TYMPTK2 | |
| SCHEMBL6931042 | 0.75 | TK1 (0.39) | TK1TYMPTK2 | |
| SCHEMBL8135550 | 0.74 | TK1 (0.37) | TK1TYMPTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0773950-B1 | LINKED PEPTIDE NUCLEIC ACIDS | ISIS PHARMACEUTICALS INC (US) | 2007-08-22 | — | — | EP | disclosed |
| US-20030105286-A1 | Linked peptide nucleic acids | EGHOLM MICHAEL (US) | 2003-06-05 | — | — | US | disclosed |
| US-6441130-B1 | FORM TRIPLE STRANDED STRUCTURES WITH NUCLEIC ACIDS | ISIS PHARMACEUTICALS, INC. | 2002-08-27 | — | — | US | disclosed |
| EP-0773950-A4 | LINKED PEPTIDE NUCLEIC ACIDS | ISIS PHARMACEUTICALS INC (US) | 2000-05-17 | — | — | EP | disclosed |
| EP-0773950-A1 | LINKED PEPTIDE NUCLEIC ACIDS | ISIS PHARMACEUTICALS, INC. (US) | 1997-05-21 | — | — | EP | disclosed |
| WO-1996002558-A1 | LINKED PEPTIDE NUCLEIC ACIDS | ISIS PHARMACEUTICALS, INC. (US) | 1996-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105286-A1 | Linked peptide nucleic acids | RNGTT, NT5C3B, DPYD | TK1 56/4885TYMP 14/4885TK2 152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.